1 Estimating effects of serum vitamin B12 levels on psychiatric disorders and cognitive

- 2 impairment: a Mendelian randomization study
- 3 Tianyuan Lu^{1,*} and Andrew D. Paterson^{2,3,4,*}
- 4
- ⁵ ¹Department of Statistical Sciences, Faculty of Arts and Science, University of Toronto, Toronto,
- 6 ON, Canada
- 7 ²Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON,
- 8 Canada
- ³Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON,
 Canada
- ⁴Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada
- 12
- 13 *Correspondence to:
- 14 Tianyuan Lu (<u>tianyuan.lu@mail.mcgill.ca</u>) and Andrew D. Paterson
- 15 (andrew.paterson@sickkids.ca)
- 16 Address: Program in Genetics & Genomic Biology, The Hospital for Sick Children Research
- 17 Institute, PGCRL Rm 12.9835, 686 Bay Street, Toronto, ON M5G 0A4, Canada
- 18

19 Abstract (For Translational Psychiatry: unstructured; 300 words)

20 Vitamin B12 deficiency can lead to pernicious anemia, various neuropsychiatric diseases, and 21 cognitive decline. However, it is unclear whether increasing vitamin B12 levels can help to 22 prevent the onset of psychiatric disorders and cognitive impairment in the general population. 23 Leveraging large-scale genome-wide association studies (GWASs), we conducted Mendelian 24 randomization (MR) analyses to estimate the potential effects of serum vitamin B12 levels on eight psychiatric disorders, as well as educational attainment and cognitive performance. We 25 performed sensitivity analyses by excluding genetic instruments that demonstrated potential 26 horizontal pleiotropy. We conducted additional MR analyses utilizing within-sibship studies for 27 depressive symptoms, educational attainment, and cognitive performance to mitigate bias due 28 29 to potential residual confounding in GWASs. As a positive control, we confirmed that a one 30 standard deviation increase in genetically increased vitamin B12 levels was strongly associated 31 with a decreased odds of developing pernicious anemia (odds ratio, OR = 0.24; 95% confidence interval, CI: 0.15-0.40; p-value = 2.1x10⁻⁸). In contrast, MR estimates of vitamin B12 effects on all 32 eight psychiatric disorders, educational attainment and cognitive performance largely 33 34 overlapped with the null. In particular, based on the three most well-powered GWASs, a one 35 standard deviation increase in genetically predicted vitamin B12 levels was associated with an OR of 1.01 for depression (95% CI: 0.97-1.04; p-value = 0.74), a 7.7×10^{-3} standard deviation 36 increase in educational attainment (95% CI: $-1.0x10^{-2}-2.5x10^{-2}$; p-value = 0.39) and a $1.3x10^{-2}$ 37 standard deviation increase in cognitive performance (95% CI: $-8.8 \times 10^{-3} - 3.5 \times 10^{-2}$; p-value = 0.24). 38 No significant associations between genetically predicted vitamin B12 levels and any of the 39 40 outcomes were identified in sensitivity analyses excluding pleiotropic genetic instruments or MR 41 analyses based on within-sibship studies. In summary, our findings suggest that increasing serum 42 vitamin B12 levels may not protect against the investigated psychiatric disorders or cognitive 43 impairment in the general population.

45 Introduction

Vitamin B12, also known as cobalamin, is an important water-soluble vitamin¹. Together with folate, vitamin B12 has multiple essential roles in various biological processes, such as DNA synthesis and methylation, maturation of erythrocytes, as well as fatty acid and amino acid metabolism²⁻⁴. Vitamin B12 also contributes to the maintenance of the nervous system via the synthesis of myelin and neuronal regeneration^{5, 6}. For humans, vitamin B12 is obtained exclusively from dietary intake¹.

52

Vitamin B12 deficiency affects a significant proportion of the global population, including both 53 females and males and across all age groups^{7, 8}. Vitamin B12 deficiency defined as serum vitamin 54 55 B12 levels < 148 pmol per litre has been estimated to affect 2.9% of the adult population in the United States⁹. Untreated vitamin B12 deficiency can lead to pernicious anemia and can result in 56 57 neurological manifestations, such as peripheral neuropathy, ataxia, various psychiatric disorders, as well as cognitive impairment^{7, 8, 10}. Amongst individuals with depression or schizophrenia, 58 randomized placebo-controlled trials have shown that folate plus vitamin B12 supplementation 59 may preserve cognitive functions and delay the disease progression¹¹⁻¹³. However, randomized 60 placebo-controlled trials have not elucidated whether increasing vitamin B12 levels through 61 62 supplementation can help to prevent the onset of psychiatric disorders and cognitive impairment in the general population¹⁴, where the majority does not have clinical vitamin B12 deficiency. 63 64 Although a longitudinal study indicated that vitamin B12 levels are negatively associated with incident depressive symptoms in older adults¹⁵, these observational associations may be subject 65 to confounding factors that are difficult to fully account for, such as socioeconomic status, 66 67 lifestyle factors, and comorbidities.

68

69 Mendelian randomization (MR) provides an effective and inexpensive alternative for estimating 70 potential effects of vitamin B12 levels in the general population. MR employs genetic variants as instruments for an exposure (i.e. vitamin B12 levels) and assesses the associations between the 71 genetically predicted exposure and the outcomes under investigation^{16, 17}. MR relies on three 72 73 instrumental variable assumptions: (1) the genetic instruments should be associated with the 74 exposure; (2) the genetic instruments should not be associated with any confounders; and (3) 75 the genetic instruments should affect the outcome through the exposure and not through other 76 mechanisms, which is known as the assumption of no horizontal pleiotropy. Given that genetic 77 variants are typically randomized at conception, the first two MR assumptions are likely fulfilled 78 by selecting variants significantly associated with serum B12 levels as genetic instruments from recent large-scale genome-wide association studies (GWASs)¹⁸, although the assumption of no 79 80 horizontal pleiotropy requires further verification.

81

MR has been adopted to evaluate the relationships between serum vitamin B12 levels and several diseases and biomarkers. Suggestive evidence has indicated that increased vitamin B12 levels may marginally increase fasting glucose while reducing beta-cell function in the pancreas¹⁹. However, no explicit associations have been identified between vitamin B12 levels and coronary artery disease, type 2 diabetes, measures of obesity, or Alzheimer's disease^{19, 20}. Recently, a phenome-wide study based on the UK Biobank confirmed the association between increased vitamin B12 levels and reduced odds of pernicious anemia²¹. However, it remains unclear

89 whether the genetically predicted vitamin B12 levels are associated with psychiatric disorders

- 90 and cognitive impairment, due to limited statistical power in previous studies.
- 91

92 Therefore, in this study, we performed MR analyses to investigate the potential effects of serum 93 vitamin B12 levels on eight common psychiatric disorders and cognitive impairment in the 94 general population. To maximize statistical power, we utilized the GWASs with the largest sample 95 sizes to date, encompassing attention-deficit/hyperactivity disorder (ADHD), anorexia nervosa, 96 anxiety disorders, autism spectrum disorder, bipolar disorder, depression, obsessive-compulsive 97 disorder (OCD), schizophrenia, as well as educational attainment and cognitive performance. 98 Multiple sensitivity analyses were performed to address potential bias arising from violations of 99 instrumental variable assumptions and residual confounding in GWASs. This study aims to 100 contribute to the understanding of whether vitamin B12 supplementation could serve as a 101 preventive measure against psychiatric disorders and cognitive impairment in the general 102 population.

104 Methods

105 Genome-wide association studies of serum vitamin B12 and folate levels

106 Serum vitamin B12 levels were measured in three cohort studies¹⁸. GWAS meta-analyses were performed based on a total of 45,576 participants of European ancestry, including 37,283 107 108 individuals from an Icelandic cohort and 8,293 individuals from two Danish cohorts. Furthermore, 109 GWAS meta-analyses for serum folate levels were performed in the same cohort studies, based on a total of 37,341 individuals. Vitamin B12 and folate levels were quantile normalized prior to 110 analysis. Details of these GWAS meta-analyses have been described previously¹⁸. Independent 111 112 genetic variants significantly associated with serum vitamin B12 and folate levels with a p-value 113 < 2.2x10⁻⁹ (Bonferroni-corrected genome-wide significance threshold accounting for 22.9 million 114 tested variants) were utilized as genetic instruments. We calculated the F-statistic of each genetic instrument, where an F-statistic > 10 would indicate a low risk of weak instrument bias²². The 115 116 genetic instruments and the mapped protein-coding genes are summarized in Supplementary 117 Table S1.

118

119 Known genotype-phenotype associations involving genetic instruments

120 To assess the potential risk of horizontal pleiotropy, we evaluated whether the selected genetic instruments have been associated with other phenotypes. We queried each genetic instrument 121 in the Open Targets Genetics database^{23, 24} (https://genetics.opentargets.org/, accessed 122 December 15, 2023), which includes existing GWASs in the GWAS Catalog as well as GWASs 123 conducted using the UK Biobank or FinnGen resources²⁵⁻²⁸. After excluding associations with 124 125 vitamin B12 levels, folate levels, and pernicious anemia, we considered genetic instruments that 126 are associated with one to five other phenotypes (p-value $< 5.0 \times 10^{-8}$) to be subject to a moderate 127 risk of horizontal pleiotropy, and those associated with more than five other phenotypes to be 128 subject to a high risk of horizontal pleiotropy. The following analyses focused on vitamin B12 129 levels because both of the two genetic instruments for folate levels demonstrated potential 130 horizontal pleiotropy. All genotype-phenotype associations involving genetic instruments are 131 summarized in Supplementary Table S2.

132

133 Association between vitamin B12 levels and pernicious anemia

134 As a positive control, we assessed whether genetically predicted vitamin B12 and folate levels 135 were associated with pernicious anemia. We obtained UK Biobank exome-based association statistics from the Genebass database²⁹ (https://app.genebass.org/, accessed October 19, 2023) 136 137 for all genetic instruments were available in the exome-sequencing data. Details regarding quality control, exome-side association studies, and data curation have been described previously²⁹. We 138 139 queried each genetic instrument for its associations with various types of anemia, based on 140 International Classification of Diseases version 10 (ICD-10) codes or self-reported physician-made 141 diagnoses.

142

143 We performed MR to assess the association between the genetically predicted vitamin B12 levels 144 and each type of anemia using the weighted median method. This method can tolerate the

inclusion of invalid genetic instruments and can provide consistent estimates with up to 50% of

- 146 the information coming from invalid genetic instruments³⁰. We additionally performed MR using
- 147 the inverse variance weighted regression, penalized weighted median, simple mode, weighted

148 mode, and MR-Egger method, respectively. A nominally significant MR-Egger intercept (p-value

149 < 0.05) was considered evidence of directional pleiotropy³¹. We derived Wald ratio estimates to

assess the association between the genetically predicted folate levels and each type of anemia,

since only one genetic instrument for folate levels was available in the UK Biobank exomesequencing data. MR analyses were conducted using the TwoSampleMR R package version

- sequencing data. MR analyses were conducted using the TwoSampleMR R pa
 0.5.6³².
- 154

155 Genome-wide association studies of psychiatric disorders, educational attainment, and 156 cognitive performance

- 157 The summary statistics of the most recent large-scale GWAS meta-analyses for eight psychiatric 158 disorders were obtained from the Psychiatric Genomics Consortium, including ADHD³³ (N cases = 20,183, N controls = 35,191), anorexia nervosa³⁴ (N cases = 16,992, N controls = 55,525), anxiety 159 160 disorders³⁵ (N cases = 7,016, N controls = 14,745), autism spectrum disorder³⁶ (N cases = 18,381, N controls = 27,969), bipolar disorder³⁷ (N cases = 41,917, N controls = 371,549), depression³⁸ (N 161 cases = 246,363, N controls = 561,190), OCD³⁹ (N cases = 2,688, N controls = 7,037), and 162 schizophrenia⁴⁰ (N cases = 69,369, N controls = 236,642). The GWAS summary statistics for 163 164 educational attainment⁴¹ (N = 765,283), measured as number of years of schooling completed, were obtained from the Social Science Genetic Association Consortium. The GWAS summary 165 statistics for cognitive performance⁴² (N = 257,828), guantified based on various cognitive tests, 166 167 were obtained from the Cognitive Genomics Consortium. Participants of these study cohorts 168 were predominantly of European ancestry. Details of these GWASs are summarized in Table 1.
- 169

170 Power calculation for Mendelian randomization

171 To assess the likelihood of type II errors, we conducted power calculations for MR analyses using the mRnd R package⁴³ (https://shiny.cnsgenomics.com/mRnd/, accessed December 15, 2023). 172 173 The type I error rate was set at 5%. For each psychiatric disorder, the statistical power was derived by assuming a true odds ratio (OR) per one standard deviation change in vitamin B12 174 175 levels of 1.01, 1.02, 1.03, 1.04, 1.05, 1.10, or 1.20, respectively. For educational attainment and 176 cognitive performance, the statistical power was derived by assuming a true association with a 177 magnitude of 0.01, 0.02, 0.03, 0.04, 0.05, 0.10, or 0.20 per one standard deviation change in 178 vitamin B12 levels, respectively.

179

Associations between vitamin B12 levels and psychiatric disorders, educational attainment, and cognitive performance

182 Similar to positive control analyses, we performed MR to assess the association between the 183 genetically predicted vitamin B12 levels and each of the outcomes. MR estimates derived using 184 the weighted median method were reported as primary results. Associations with a p-value < 5.0x10⁻³ (Bonferroni-corrected significance threshold accounting for 10 outcomes) were 185 considered significant. Secondary analyses were performed using the inverse variance weighted 186 187 regression, penalized weighted median, simple mode, weighted mode, and MR-Egger method, 188 respectively. For folate levels, since two genetic instruments were used, the inverse variance 189 weighted regression estimates were derived to assess the association with each outcome. 190

191 Sensitivity analyses excluding pleiotropic genetic instruments

- 192 To mitigate potential bias from horizontal pleiotropy, we excluded genetic instruments that were
- subject to a high risk of horizontal pleiotropy and repeated the MR analyses for vitamin B12 levels.
- 194 Subsequently, we further excluded genetic instruments that were subject to a moderate risk of
- 195 horizontal pleiotropy and again repeated the MR analyses for vitamin B12 levels.
- 196

197 Within-sibship genome-wide association studies

198 Since population GWAS estimates for psychiatric disorders, educational attainment, and 199 cognitive performance may be confounded by uncontrolled demographic and indirect genetic 200 effects, we repeated the MR analyses leveraging within-sibship GWAS estimates that were 201 available for depressive symptoms, educational attainment, and cognitive performance⁴⁴. 202 Notably, unlike in the GWAS for depression, depressive symptoms were measured using various rating scales and standardized to be a continuous outcome⁴⁴. European ancestry-specific within-203 204 sibship GWAS summary statistics were obtained from the Within Family Consortium⁴⁴. Details of 205 these GWASs have been described previously and are summarized in **Supplementary Table S3**. 206

207 Results

208 Mendelian randomization confirmed association between vitamin B12 levels and pernicious 209 anemia

210 An overview of this study is illustrated in Figure 1. Meta-analyses of GWASs for serum vitamin 211 B12 levels identified 11 genetic instruments (p-value < 2.2×10^{-9} ; Supplementary Table S1). 212 Interestingly, all of these 11 variants are missense or stop-gain variants of protein-coding genes (Supplementary Table S1). Of these genetic instruments, the minimal F-statistic was 43.14, 213 214 suggesting a low risk of weak instrument bias (Supplementary Table S1). Notably, some of these 215 genetic instruments may pose a risk of horizontal pleiotropy. For instance, rs602662, a missense 216 variant of FUT2, was subject to a high risk of horizontal pleiotropy (Supplementary Table S2). 217 Missense variants in MUT, FUT6, CD320, and CUBN were subject to a moderate risk of horizontal pleiotropy due to their associations with other phenotypes, such as liver function biomarkers, 218 219 lipid levels, and height (Supplementary Table S2).

220

Based on the UK Biobank, we confirmed that a one standard deviation increase in genetically predicted vitamin B12 levels was strongly associated with an OR of 0.27 for vitamin B12 deficiency anemia based on ICD-10 codes (95% CI: 0.19-0.40; p-value = $1.0x10^{-11}$), as well as an OR of 0.24 for self-reported pernicious anemia (95% CI: 0.15-0.40; p-value = $2.1x10^{-8}$; **Figure 2** and **Supplementary Table S4**). Meanwhile, the genetically predicted vitamin B12 levels were not associated with other types of anemia (**Figure 2** and **Supplementary Table S4**). MR estimates derived using different methods were highly consistent (**Supplementary Table S4**).

228

229 In addition, two independent genetic variants, rs1801133 and rs652197, were significantly 230 associated with serum folate levels (p-value < 2.2x10⁻⁹; Supplementary Table S1). However, 231 rs1801133, a missense variant of MTHFR, demonstrated a high risk of horizontal pleiotropy, while 232 rs652197, an intronic variant of FOLR3, has been associated with serum 25-hydroxyvitamin D 233 levels in previous studies (Supplementary Table S2). As expected, the genetically predicted folate 234 levels were also associated with a reduced odds of vitamin B12 deficiency anemia based on ICD-10 codes (OR = 0.30; 95% CI: 0.18-0.49; p-value = 2.3×10^{-6}) and self-reported pernicious anemia 235 236 (OR = 0.29; 95% CI: 0.14-0.60; p-value = 9.3x10⁻⁴; Figure 2 and Supplementary Table S4). 237 Although folate levels were predicted to reduce the odds of folate deficiency anemia, this 238 association was not significant, likely due to the small number of folate deficiency anemia cases 239 (Figure 2 and Supplementary Table S4).

240

241 Genetically predicted vitamin B12 levels were not associated with psychiatric disorders, 242 educational attainment, and cognitive performance

The large-scale GWASs for psychiatric disorders, educational attainment, and cognitive performance ensured sufficient statistical power in MR analyses (**Table 1** and **Supplementary Table S5**). Of the eight psychiatric disorders under investigation, the GWAS meta-analyses for depression had the largest sample size. As a result, with a type I error rate of 5%, MR analyses with depression as the outcome could achieve a power ≥ 80% when the true OR per one standard deviation change in vitamin B12 levels was equal to or greater than 1.03 (**Supplementary Table S5**). Comparably, MR analyses for educational attainment and cognitive performance could

achieve a power of 100% and 94%, respectively, when the true association had a magnitude of 0.03 per one standard deviation change in vitamin B12 levels (**Supplementary Table S5**).

252

253 Despite sufficient statistical power, MR analyses did not detect any significant associations 254 between genetically predicted vitamin B12 levels and any outcomes (Figure 3 and 255 Supplementary Table S5). For example, a one standard deviation increase in genetically predicted vitamin B12 levels was associated with an OR of 1.01 for depression (95% CI: 0.97-1.04; 256 p-value = 0.74), as well as a 7.7×10^{-3} and 1.3×10^{-2} standard deviation increase in educational 257 attainment (95% CI: -1.0x10⁻²-2.5x10⁻²; p-value = 0.39) and cognitive performance (95% CI: -258 8.8x10⁻³-3.5x10⁻²; p-value = 0.24), respectively (Figure 3 and Supplementary Table S5). The 259 260 estimated associations between folate levels and the outcomes also largely overlapped with the null (Figure 3 and Supplementary Table S6). 261

262

263 Furthermore, no associations were detected between genetically predicted vitamin B12 levels and any outcomes in sensitivity analyses where the genetic instruments demonstrating potential 264 265 horizontal pleiotropy were excluded (Figure 3 and Supplementary Tables S7 and S8). In fact, 266 none of the tested associations had a nominal p-value < 0.05 in the primary analyses using the weighted median method (Figure 3). The estimates derived using alternative methods were 267 268 highly consistent with the primary results, with the only exception that with the penalized 269 weighted median method, a one standard deviation increase in genetically predicted vitamin B12 levels was associated with an OR of 0.82 for ADHD (95% CI: 0.72-0.93; p-value = 2.1x10⁻³; 270 271 Supplementary Figure S1 and Supplementary Table S5). Nevertheless, this association was not 272 detected after excluding the highly pleiotropic genetic instrument in FUT2 (Supplementary Table 273 **S7**) as well as after further excluding the moderately pleiotropic genetic instruments 274 (Supplementary Table S8).

275

276 Sensitivity analyses based on within-sibship genome-wide association studies

277 MR analyses leveraging within-sibship GWASs for depressive symptoms, educational attainment, and cognitive performance did not identify any significant associations with genetically predicted 278 279 vitamin B12 levels (Figure 4A). Specifically, a one standard deviation increase in genetically predicted vitamin B12 levels was associated with a 5.4x10⁻² standard deviation decrease in 280 281 depressive symptoms (95% CI: $-0.14-3.6 \times 10^{-2}$; p-value = 0.24), as well as a 5.6 \times 10^{-3} and 3.9 \times 10^{-2} standard deviation increase in educational attainment (95% CI: -4.3x10⁻²-5.5x10⁻²; p-value = 0.82) 282 283 and cognitive performance (95% CI: -6.6×10^{-2} -0.14; p-value = 0.47), respectively (Figure 4A and 284 Supplementary Table S9). These estimates were consistent with those obtained using alternative 285 MR methods (Figure 4B-D and Supplementary Table S9). 286

287 Discussion

288 Vitamin B12 has important roles in one-carbon metabolism as both an enzyme cofactor or substrate¹. Individuals with vitamin B12 deficiency can develop pernicious anemia as well as 289 neuropsychiatric diseases^{7, 8}. However, it remains unclear whether the general population may 290 291 benefit from vitamin B12 supplementation for protection against psychiatric disorders and 292 cognitive impairment. In this study, we performed MR analyses to estimate the potential effects 293 of serum vitamin B12 levels on eight psychiatric disorders, educational attainment, and cognitive 294 performance. We did not detect any significant associations between genetically predicted 295 serum vitamin B12 levels and any of these outcomes.

296

297 Our study has several strengths. First, we employed genetic instruments that were protein-298 altering variants affecting crucial genes in the absorption, transport, or enzymatic reactions of 299 vitamin B12 for MR analyses¹⁸. This approach effectively mitigated bias arising from unmeasured 300 confounding and reverse causation. Second, the use of large-scale GWASs for the outcomes, 301 particularly depression, educational attainment, and cognitive performance, minimized the 302 likelihood of type II errors, given the reporting of null associations. These results were compared 303 to the positive control, where genetically increased vitamin B12 levels exhibited strong protective 304 effects against pernicious anemia, thereby supporting the validity of our analyses. Third, 305 consistent MR estimates were obtained in sensitivity analyses where pleiotropic variants were 306 removed, safeguarding an indispensable instrumental variable assumption of MR. Nevertheless, 307 MR estimates for folate levels were more prone to bias due to horizontal pleiotropy, thus 308 interpreting the results involving folate levels requires extra caution. Fourth, MR analyses based 309 on within-sibship GWASs for depressive symptoms, educational attainment, and cognitive 310 performance further reduced the risk of confounding due to uncontrolled population 311 stratification, assortative mating, or indirect genetic effects⁴⁴.

312

313 Our study has a clear and important implication that, in the general population, vitamin B12 314 supplementation is unlikely to meaningfully reduce the risks of the investigated psychiatric 315 disorders or significantly improve educational attainment or cognitive performance. These 316 results may discourage randomized placebo-controlled trials amongst individuals without clinical 317 vitamin B12 deficiency, while encouraging the identification of other risk factors and preventive 318 measures for psychiatric disorders and cognitive impairment. However, it is noteworthy that 319 none of the GWASs utilized in this study were based on populations selected for vitamin B12 320 deficiency. Multiple lines of evidence are still needed to ascertain the potential impact of vitamin 321 B12 or folate plus vitamin B12 supplementation on various outcomes in individuals with vitamin 322 B12 deficiency.

323

Some limitations of our study should be noted. First, our MR analyses relied on sex-combined GWASs and could not identify potential sex-specific effects of vitamin B12 levels, since large-scale sex-stratified GWASs for both vitamin B12 levels and the outcomes are yet to emerge. Second, our analyses were restricted to populations of European ancestry. It remains unclear whether our findings could be generalized to other populations of non-European ancestries. Third, larger GWASs for certain psychiatric disorders, such as OCD and anxiety disorders, are necessary to increase the statistical power of MR analyses for identifying potential effects of small magnitudes.

Fourth, our MR analyses could estimate population-averaged associations between vitamin B12 331 332 levels and the outcomes, but not potential dose-dependent effects of vitamin B12 levels, which 333 would require availability of both vitamin B12 measurements and the outcomes in the same study population^{45, 46}. Fifth, one of the genetic instruments, rs371753672, a missense variant of 334 335 MMACHC, was not available in any GWASs utilized in this study due to its low minor allele 336 frequency. However, this variant only captures a small proportion of variance in vitamin B12 337 levels. Last, our results do not provide information on whether serum vitamin B12 levels may 338 influence the progression of psychiatric disorders or cognitive impairment, as the genetic 339 architecture underlying disease progression may differ from that underlying disease 340 pathogenesis. We anticipate that future investigations will more comprehensively illuminate the 341 role of vitamin B12 in various psychiatric disorders and cognitive impairment in diverse 342 populations.

343

In conclusion, through MR analyses, we demonstrated that genetically predicted serum vitamin B12 levels were not associated with eight psychiatric disorders, educational attainment, or cognitive performance. Our findings indicate that vitamin B12 supplementation is unlikely to offer protection against these psychiatric disorders or cognitive impairment in the general population.

350 Author contributions

T.L. and A.D.P. conceptualized the study. T.L. curated the data, performed the analyses, and wrote the original draft. T.L. and A.D.P. interpreted the results, and reviewed and edited the manuscript critically.

354

355 Acknowledgements

We thank David S. Rosenblatt and David Watkins for helpful discussions. T.L. has been supported by a Schmidt AI in Science Postdoctoral Fellowship. The funders have no role in study design; collection, management, analysis and interpretation of data; or the decision to submit for publication.

360

361 *Conflicts of interest*

362 T.L. has been providing consulting services to 5 Prime Sciences Inc., which was not involved in

363 the design, execution, analysis, or interpretation of the study. The other authors declare no

- 364 conflicts of interest.
- 365

366 References

1. Zempleni J, Suttie JW, Gregory III JF, Stover PJ. *Handbook of vitamins*. CRC Press; 2013.

Bohnsack BL, Hirschi KK. Nutrient regulation of cell cycle progression. *Annu Rev Nutr.* 2004;24:433-53. doi:10.1146/annurev.nutr.23.011702.073203

3. O'Leary F, Samman S. Vitamin B12 in health and disease. *Nutrients*. Mar 2010;2(3):299 316. doi:10.3390/nu2030299

Stover PJ. Physiology of folate and vitamin B12 in health and disease. *Nutr Rev.* Jun
 2004;62(6 Pt 2):S3-12; discussion S13. doi:10.1111/j.1753-4887.2004.tb00070.x

5. Calderon-Ospina CA, Nava-Mesa MO. B Vitamins in the nervous system: Current knowledge of the biochemical modes of action and synergies of thiamine, pyridoxine, and cobalamin. *CNS Neurosci Ther*. Jan 2020;26(1):5-13. doi:10.1111/cns.13207

3776.Briani C, Dalla Torre C, Citton V, et al. Cobalamin deficiency: clinical picture and378radiological findings. Nutrients. Nov 15 2013;5(11):4521-39. doi:10.3390/nu5114521

379 7. Green R, Allen LH, Bjørke-Monsen A-L, et al. Vitamin B12 deficiency. *Nature reviews*380 *Disease primers*. 2017;3(1):1-20.

381 8. Stabler SP. Vitamin B12 deficiency. *New England Journal of Medicine*. 2013;368(2):149382 160.

Bailey RL, Carmel R, Green R, et al. Monitoring of vitamin B-12 nutritional status in the
United States by using plasma methylmalonic acid and serum vitamin B-12. *Am J Clin Nutr*. Aug
2011;94(2):552-61. doi:10.3945/ajcn.111.015222

Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by
cobalamin deficiency in the absence of anemia or macrocytosis. *N Engl J Med.* Jun 30
1988;318(26):1720-8. doi:10.1056/NEJM198806303182604

Roffman JL, Lamberti JS, Achtyes E, et al. Randomized multicenter investigation of folate
plus vitamin B12 supplementation in schizophrenia. *JAMA Psychiatry*. May 2013;70(5):481-9.
doi:10.1001/jamapsychiatry.2013.900

Walker JG, Batterham PJ, Mackinnon AJ, et al. Oral folic acid and vitamin B-12
supplementation to prevent cognitive decline in community-dwelling older adults with
depressive symptoms—the Beyond Ageing Project: a randomized controlled trial. *The American journal of clinical nutrition*. 2012;95(1):194-203.

Almeida OP, Ford AH, Flicker L. Systematic review and meta-analysis of randomized
placebo-controlled trials of folate and vitamin B12 for depression. *Int Psychogeriatr.* May
2015;27(5):727-37. doi:10.1017/S1041610215000046

Walker JG, Mackinnon AJ, Batterham P, et al. Mental health literacy, folic acid and vitamin
B12, and physical activity for the prevention of depression in older adults: randomised controlled
trial. *Br J Psychiatry*. Jul 2010;197(1):45-54. doi:10.1192/bjp.bp.109.075291

402 15. Laird EJ, O'Halloran AM, Molloy AM, et al. Low vitamin B12 but not folate is associated
403 with incident depressive symptoms in community-dwelling older adults: a 4-year longitudinal
404 study. *British Journal of Nutrition*. 2021:1-8.

405 16. Skrivankova VW, Richmond RC, Woolf BA, et al. Strengthening the reporting of 406 observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation 407 and elaboration. *bmj*. 2021;375

408 17. Skrivankova VW, Richmond RC, Woolf BA, et al. Strengthening the Reporting of
409 Observational Studies in Epidemiology using Mendelian Randomization: the STROBE-MR
410 Statement. JAMA. 2021;326(16):1614-1621.

411 18. Grarup N, Sulem P, Sandholt CH, et al. Genetic architecture of vitamin B12 and folate
412 levels uncovered applying deeply sequenced large datasets. *PLoS Genet*. Jun 2013;9(6):e1003530.
413 doi:10.1371/journal.pgen.1003530

414 19. Moen GH, Qvigstad E, Birkeland KI, Evans DM, Sommer C. Are serum concentrations of 415 vitamin B-12 causally related to cardiometabolic risk factors and disease? A Mendelian 416 randomization study. *Am J Clin Nutr*. Aug 1 2018;108(2):398-404. doi:10.1093/ajcn/nqy101

41720.Gagliano Taliun SA. Genetic determinants of low vitamin B12 levels in Alzheimer's disease418risk. Alzheimers Dement (Amst). Dec 2019;11:430-434. doi:10.1016/j.dadm.2019.04.007

21. Dib MJ, Ahmadi KR, Zagkos L, et al. Associations of Genetically Predicted Vitamin B(12)
Status across the Phenome. *Nutrients*. Nov 26 2022;14(23)doi:10.3390/nu14235031

421 22. Burgess S, Thompson SG, Collaboration CCG. Avoiding bias from weak instruments in
422 Mendelian randomization studies. *Int J Epidemiol*. Jun 2011;40(3):755-64.
423 doi:10.1093/ije/dyr036

424 23. Ghoussaini M, Mountjoy E, Carmona M, et al. Open Targets Genetics: systematic
425 identification of trait-associated genes using large-scale genetics and functional genomics.
426 *Nucleic Acids Res.* Jan 8 2021;49(D1):D1311-D1320. doi:10.1093/nar/gkaa840

427 24. Ochoa D, Hercules A, Carmona M, et al. Open Targets Platform: supporting systematic
428 drug-target identification and prioritisation. *Nucleic Acids Res.* Jan 8 2021;49(D1):D1302-D1310.
429 doi:10.1093/nar/gkaa1027

430 25. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping
431 and genomic data. *Nature*. Oct 2018;562(7726):203-209. doi:10.1038/s41586-018-0579-z

432 26. Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a well433 phenotyped isolated population. *Nature*. Jan 2023;613(7944):508-518. doi:10.1038/s41586-022434 05473-8

435 27. Buniello A, MacArthur JAL, Cerezo M, et al. The NHGRI-EBI GWAS Catalog of published
436 genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.*437 Jan 8 2019;47(D1):D1005-D1012. doi:10.1093/nar/gky1120

438 28. MacArthur J, Bowler E, Cerezo M, et al. The new NHGRI-EBI Catalog of published genome439 wide association studies (GWAS Catalog). *Nucleic Acids Res.* Jan 4 2017;45(D1):D896-D901.
440 doi:10.1093/nar/gkw1133

441 29. Karczewski KJ, Solomonson M, Chao KR, et al. Systematic single-variant and gene-based
442 association testing of thousands of phenotypes in 394,841 UK Biobank exomes. *Cell Genom*. Sep
443 14 2022;2(9):100168. doi:10.1016/j.xgen.2022.100168

444 30. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian 445 randomization with some invalid instruments using a weighted median estimator. *Genetic* 446 *epidemiology*. 2016;40(4):304-314.

Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments:
effect estimation and bias detection through Egger regression. *International journal of epidemiology*. 2015;44(2):512-525.

450 32. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal 451 inference across the human phenome. *Elife*. May 30 2018;7doi:10.7554/eLife.34408

452 33. Demontis D, Walters RK, Martin J, et al. Discovery of the first genome-wide significant risk
453 loci for attention deficit/hyperactivity disorder. *Nat Genet*. Jan 2019;51(1):63-75.
454 doi:10.1038/s41588-018-0269-7

455 34. Watson HJ, Yilmaz Z, Thornton LM, et al. Genome-wide association study identifies eight 456 risk loci and implicates metabo-psychiatric origins for anorexia nervosa. *Nat Genet*. Aug 457 2019;51(8):1207-1214. doi:10.1038/s41588-019-0439-2

45835.Otowa T, Hek K, Lee M, et al. Meta-analysis of genome-wide association studies of anxiety459disorders. *Mol Psychiatry*. Oct 2016;21(10):1485. doi:10.1038/mp.2016.11

- 460 36. Grove J, Ripke S, Als TD, et al. Identification of common genetic risk variants for autism 461 spectrum disorder. *Nat Genet*. Mar 2019;51(3):431-444. doi:10.1038/s41588-019-0344-8
- 462 37. Mullins N, Forstner AJ, O'Connell KS, et al. Genome-wide association study of more than
 463 40,000 bipolar disorder cases provides new insights into the underlying biology. *Nat Genet*. Jun
 464 2021;53(6):817-829. doi:10.1038/s41588-021-00857-4

465 38. Howard DM, Adams MJ, Clarke TK, et al. Genome-wide meta-analysis of depression
466 identifies 102 independent variants and highlights the importance of the prefrontal brain regions.
467 Nat Neurosci. Mar 2019;22(3):343-352. doi:10.1038/s41593-018-0326-7

468 39. International Obsessive Compulsive Disorder Foundation Genetics C, Studies OCDCGA.
469 Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis.
470 *Mol Psychiatry*. May 2018;23(5):1181-1188. doi:10.1038/mp.2017.154

470 *Not Psychiatry*. May 2018;23(5):1181-1188. doi:10.1038/mp.2017.154 471 40. Trubetskoy V, Pardinas AF, Qi T, et al. Mapping genomic loci implicates genes and synaptic

- 40. Trubetskoy v, Pardinas AF, GFT, et al. Mapping genomic loci implicates genes and synaptic
 472 biology in schizophrenia. *Nature*. Apr 2022;604(7906):502-508. doi:10.1038/s41586-022-04434473 5
- 474 41. Okbay A, Wu Y, Wang N, et al. Polygenic prediction of educational attainment within and
 475 between families from genome-wide association analyses in 3 million individuals. *Nature genetics*.
 476 2022;54(4):437-449.
- 477 42. Lee JJ, Wedow R, Okbay A, et al. Gene discovery and polygenic prediction from a genome478 wide association study of educational attainment in 1.1 million individuals. *Nat Genet*. Jul 23
 479 2018;50(8):1112-1121. doi:10.1038/s41588-018-0147-3

480 43. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian 481 randomization studies. *Int J Epidemiol*. Oct 2013;42(5):1497-501. doi:10.1093/ije/dyt179

482 44. Howe LJ, Nivard MG, Morris TT, et al. Within-sibship genome-wide association analyses
483 decrease bias in estimates of direct genetic effects. *Nat Genet*. May 2022;54(5):581-592.
484 doi:10.1038/s41588-022-01062-7

485 45. Emerging Risk Factors Collaboration E-CVDVDSC. Estimating dose-response relationships 486 for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and 487 Mendelian randomisation analyses. *Lancet Diabetes Endocrinol*. Jan 2024;12(1):e2-e11. 488 doi:10.1016/S2213-8587(23)00287-5

489 46. Lu T, Nakanishi T, Yoshiji S, Butler-Laporte G, Greenwood CMT, Richards JB. Dose490 dependent Association of Alcohol Consumption With Obesity and Type 2 Diabetes: Mendelian
491 Randomization Analyses. *The Journal of Clinical Endocrinology & Metabolism*.
492 2023;108(12):3320-3329. doi:10.1210/clinem/dgad324

Outcome Participating cohorts Cases Controls Total A Danish cohort collected by the 20,183 35,191 55,374 Attentiondeficit/hyperactivity Lundbeck Foundation Initiative for disorder Integrative Psychiatric Research, and 11 European, North American and Chinese cohorts aggregated by Psychiatric Genomics the Consortium Anorexia nervosa Thirty-three European ancestry 16,992 55,525 72,517 cohorts from 17 countries, including the Anorexia Nervosa Genetics Initiative and the Eating Disorders Working Group of the Psychiatric Genomics Consortium Nine European ancestry cohorts in Anxiety disorders 7,016 14,745 21,761 the Anxiety NeuroGenetics Study Consortium Autism spectrum A Danish cohort collected by the 18,381 27,969 46,350 disorder Lundbeck Foundation Initiative for Integrative Psychiatric Research Bipolar disorder Fifty-seven cohorts collected in 41,917 371,549 413,466 Europe, North America and Australia Depression Twenty-nine European ancestry 246,363 561,190 807,553 cohorts, the UK Biobank, and a discovery subset of 23andMe Obsessive-7,037 9,725 European ancestry individuals from 2,688 compulsive disorder the International Obsessive Compulsive Disorder Foundation Genetics Collaborative and OCD Collaborative Genetics Association Studies Schizophrenia Ninety cohorts including ~80% 69,369 236,642 306,011 European ancestry participants and ~20% East Asian ancestry participants Educational Sixty-nine 765,283 European ancestry attainment⁺ cohorts in the Social Science Genetic Association Consortium and the UK Biobank European ancestry individuals Cognitive Twenty-four European ancestry 257,828 performance[‡] cohorts in the Cognitive Genomics Consortium and the UK Biobank European ancestry individuals

Table 1. Genome-wide association studies of psychiatric disorders, educational attainment, and cognitive performance.

[†]Educational attainment was measured as number of years of schooling completed [‡]Cognitive performance was quantified based on various tests conducted in each study cohort



Figure 1. Overview of study design. Summary statistics of large-scale genome-wide association studies were obtained for serum vitamin B12 and folate levels, eight psychiatric disorders, educational attainment, and cognitive performance. Mendelian randomization and multiple sensitivity analyses were performed to estimate the potential effects of vitamin B12 and folate levels.



Figure 2. Associations between genetically predicted vitamin B12 and folate levels and various types of anemia. Mendelian randomization estimates obtained using the weighted median method and the Wald ratio method are illustrated for vitamin B12 levels and folate levels, respectively.



Figure 3. Associations between genetically predicted vitamin B12 and folate levels and eight psychiatric disorders, educational attainment, and cognitive performance. Sensitivity analyses for vitamin B12 levels were performed after excluding genetic instruments that were potentially subject to horizontal pleiotropy. Mendelian randomization estimates obtained using the weighted median method and the inverse variance weighted regression method are illustrated for vitamin B12 levels and folate levels, respectively.



Figure 4. Estimated effects of vitamin B12 levels based on within-sibship studies. (A) Associations between genetically predicted vitamin B12 and depressive symptoms, educational attainment, and cognitive performance. Mendelian randomization estimates obtained using the weighted median method are illustrated. Scatter plots comparing the genetic instrument-outcome and the genetic instrument-vitamin B12 levels associations are illustrated for (B) depressive symptoms, (C) educational attainment, and (D) cognitive performance. The mapped genes of the respective genetic instruments are indicated. The slopes of the colored lines represent estimates obtained through different Mendelian randomization methods.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.23.24301678; this version posted January 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



Figure S1. Scatter plots comparing the genetic instrument-outcome and the genetic instrumentexposure associations. Primary results were obtained using the weighted median method and the inverse variance weighted regression method for vitamin B12 levels and folate levels, respectively. The mapped genes of the respective genetic instruments are indicated. The slopes of the colored lines represent estimates obtained through different Mendelian randomization methods.